drugset / Trial / NCT03487211

Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia

NCT03487211

Phase 2/3 Completed 200 enrolled Shaheed Zulfiqar Ali Bhutto Medical University
RandomizedParallel-groupSingle-blindTreatment

Summary

Duloxetine is FDA approved as pharmacological treatment for Fibromyalgia. The use of SSRIs has been endorsed by the 2013 Canadian guidelines. The data available for Escitalopram as a treatment modality for Fibromyalgia is limited, however small trials have demonstrated its efficacy. No head to head comparisons between escitalopram and duloxetine have been undertaken. We aim to conduct a single blind, randomized control trial to assess the comparative efficacy of duloxetine vs escitalopram in drug naive patients with newly diagnosed Fibromyalgia.

Timeline

Start
2018-04-09
Primary completion
2020-02-26
Completion
2020-02-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg Oral
Subject Escitalopram Small molecule 20 mg Oral

Indications